Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort.
Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
Patterns of Outpatient Urinalysis Testing and the Detection of Microscopic Hematuria.
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract.
Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer.
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
Reply by Authors.
Titles as indexed on PubMed.